⌘K
Loading ticker…
BioCryst Pharmaceuticals Inc · Healthcare · Pharmaceutical Products
As of 2026-06-26, BioCryst Pharmaceuticals Inc (BCRX) has a 3-month relative strength percentile of 48 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 53. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 4.6%, relative volume 2.13×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
48 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
BCRX is in a stage 2 uptrend, week 2. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 11.5% / 24.7%.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
BCRX is held by 8 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $76M notional. Top 3 carry $193M.
Top 8 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $76M |
| XBIState Street SPDR S&P Biotech ETF | 0.85% | $63M |
| IWMiShares Russell 2000 ETF | 0.07% | $53M |
| VBVanguard Small Cap ETF | 0.02% | $28M |
| VXFVanguard Extended Market ETF | 0.03% | $26M |
| IWOiShares Russell 2000 Growth ETF | 0.13% | $16M |
| VBKVanguard Small-Cap Growth ETF | 0.04% | $15M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $3M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BCRX Jan avg: -7.55% median: -9.81% win: 25% σ: 8.95% n: 4 2022-04-12 → 2026-05-29 | BCRX Feb avg: 8.02% median: 7.61% win: 75% σ: 20.08% n: 4 2022-04-12 → 2026-05-29 | BCRX Mar avg: -4.91% median: -7.77% win: 25% σ: 9.59% n: 4 2022-04-12 → 2026-05-29 | BCRX Apr avg: -5.57% median: -8.75% win: 20% σ: 14.34% n: 5 2022-04-12 → 2026-05-29 | BCRX May avg: 16.81% median: 8.67% win: 80% σ: 24.05% n: 5 2022-04-12 → 2026-05-29 | BCRX Jun avg: -5.55% median: -9.60% win: 25% σ: 13.90% n: 4 2022-04-12 → 2026-05-29 (current) | BCRX Jul avg: 4.44% median: 4.57% win: 75% σ: 11.01% n: 4 2022-04-12 → 2026-05-29 | BCRX Aug avg: 10.95% median: 10.73% win: 75% σ: 14.11% n: 4 2022-04-12 → 2026-05-29 | BCRX Sep avg: -7.75% median: -9.01% win: 0% σ: 5.17% n: 4 2022-04-12 → 2026-05-29 | BCRX Oct avg: -3.67% median: 0.92% win: 50% σ: 13.26% n: 4 2022-04-12 → 2026-05-29 | BCRX Nov avg: -0.27% median: -0.92% win: 50% σ: 5.61% n: 4 2022-04-12 → 2026-05-29 | BCRX Dec avg: -0.83% median: 1.07% win: 75% σ: 9.55% n: 4 2022-04-12 → 2026-05-29 |